Pipeline
Acute Ischemic Stroke
Anterior large vessel occlusion, alongside standard of care
- HEMERA-1 Phase 1/2 complete
- HEMERA-2 Phase 3 next
- Breakthrough Therapy · Fast Track designation
Sickle Cell Disease
Vaso-occlusive crisis
- Phase 2a
- Orphan Drug designation
When blood is not an option
Severe anemia when transfusion is not possible, emergency use
- Phase 1 complete
For clinicians and sites
HEMERA-2 sites are thrombectomy-capable stroke centers. If your center may want to take part, get in touch and we will send the protocol summary.
Prior studies
13 studies
- ACTRN12612001033831Healthy volunteers, three rising doses2012–13 · 24 enrolledPhase 1 (opens in a new tab)
- NCT01847222Healthy volunteers, rising doses2013–14 · 2 enrolled · stopped earlyPhase 1 (opens in a new tab)
- NCT01848925Sickle Cell Disease, compared with hydroxyurea2013–14 · 24 enrolledPhase 1 (opens in a new tab)
- NCT02323685Delayed cerebral ischemia after subarachnoid hemorrhage2014–16 · 12 enrolledPhase 2 (opens in a new tab)
- NCT02437422End-stage kidney disease2015 · 5 enrolledPhase 1 (opens in a new tab)
- NCT02490202Kidney transplant, delayed graft function2015–16 · 60 enrolledPhase 2/3 (opens in a new tab)
- NCT02600390Leg ulcers in Sickle Cell Disease2016 · 10 enrolledPhase 2 (opens in a new tab)
- NCT02754999Severe anemia when transfusion is not an option2016–17 · 103 enrolledPhase 1 (opens in a new tab)
- NCT02672540Sickle cell crisis, inpatient2016–17 · 34 enrolledPhase 2 (opens in a new tab)
- NCT02411708Sickle cell crisis, outpatient2016–17 · 24 enrolledPhase 2 (opens in a new tab)
- NCT04677777Acute Ischemic Stroke (HEMERA-1)2021–25 · 47 enrolledPhase 1/2 (opens in a new tab)
- ThailandThalassemia48 enrolledPhase 2
- ThailandThalassemia with pulmonary hypertension16 enrolledPhase 1